Morgan Stanley increased its stake in Amarin Corporation PLC (NASDAQ:AMRN) by 119.7% during the first quarter, Holdings Channel reports. The fund owned 1,138,992 shares of the biopharmaceutical company’s stock after buying an additional 620,577 shares during the period. Morgan Stanley’s holdings in Amarin Corporation PLC were worth $3,645,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of AMRN. Renaissance Technologies LLC boosted its position in shares of Amarin Corporation PLC by 662.8% in the fourth quarter. Renaissance Technologies LLC now owns 386,000 shares of the biopharmaceutical company’s stock valued at $1,189,000 after buying an additional 335,400 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of Amarin Corporation PLC by 0.9% in the first quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock valued at $1,266,000 after buying an additional 3,413 shares during the last quarter. Quantitative Investment Management LLC boosted its position in shares of Amarin Corporation PLC by 105.1% in the first quarter. Quantitative Investment Management LLC now owns 187,900 shares of the biopharmaceutical company’s stock valued at $601,000 after buying an additional 96,300 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of Amarin Corporation PLC by 13.3% in the first quarter. California Public Employees Retirement System now owns 533,300 shares of the biopharmaceutical company’s stock valued at $1,707,000 after buying an additional 62,800 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the last quarter. 37.60% of the stock is currently owned by institutional investors and hedge funds.

Shares of Amarin Corporation PLC (NASDAQ:AMRN) traded up 0.2145% during trading on Thursday, reaching $3.0365. 233,067 shares of the company’s stock were exchanged. The company’s market capitalization is $822.26 million. Amarin Corporation PLC has a 52-week low of $2.56 and a 52-week high of $4.47. The company has a 50 day moving average price of $3.84 and a 200-day moving average price of $3.32.

Amarin Corporation PLC (NASDAQ:AMRN) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The firm had revenue of $44.95 million during the quarter, compared to analyst estimates of $40.35 million. The business’s revenue was up 37.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.07) EPS. On average, equities analysts forecast that Amarin Corporation PLC will post ($0.21) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Amarin Corporation PLC (AMRN) Shares Bought by Morgan Stanley” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/amarin-corporation-plc-amrn-shares-bought-by-morgan-stanley/1499492.html.

Several equities analysts have recently commented on AMRN shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $5.00 price target on shares of Amarin Corporation PLC in a research report on Monday, June 12th. Zacks Investment Research cut shares of Amarin Corporation PLC from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a report on Wednesday, August 9th. BidaskClub raised shares of Amarin Corporation PLC from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 6th. Finally, Cantor Fitzgerald set a $10.00 target price on shares of Amarin Corporation PLC and gave the stock a “buy” rating in a report on Monday. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $7.35.

In other Amarin Corporation PLC news, General Counsel Joseph T. Kennedy sold 307,911 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $4.00, for a total value of $1,231,644.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.72% of the company’s stock.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Corporation PLC (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin Corporation PLC (NASDAQ:AMRN)

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.